Alkem Laboratories Limited share price
NSE: ALKEM · ISIN INE540L01014
Key numbers
- Market cap
- ₹ 63,059 Cr
- Current price
- ₹ 5,274.00
- 52-week high / low
- ₹ 5,934 / 5,051
- Stock P/E
- 29.2
- Book value
- ₹ 1,155.9
- Dividend yield
- 0.38%
- ROCE
- 20.4%
- ROE
- 17.8%
- Debt to equity
- 0.15
- Sales growth (3 yrs)
- 8.3%
- Profit growth (3 yrs)
- 32.7%
- 1-year return
- -4.9%
About Alkem Laboratories Limited
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers biosimilars, active pharmaceutical ingredients, branded and trade generics, complex generics, and consumer wellness products in therapeutic areas comprising anti infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology, central nervous system, anti-diabetic, iron deficiency, pain management, and urology, as well as vitamins, minerals, and nutrients. It also provides cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. Alkem Laboratories Limited was incorporated in 1973 and is based in Mumbai, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 3,371 | 4,001 | 3,737 | 3,603 | 3,740 |
| Operating profit | 739 | 921 | 828 | 517 | 766 |
| Net profit | 664 | 765 | 636 | 236 | 520 |
| EPS (₹) | 55.56 | 63.99 | 53.19 | 19.77 | 43.49 |
Concall summary (2026-08-20)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- So this year for around 8.5 months, our target for Occlutech is around INR400 crores of sales with breakeven EBITDA because of delays happened in case of integration.
- And -- but yes, you can see a 7% to 8% improvement in EBITDA year-on-year and we target to achieve our guidance over 3 to 4 years.
Growth & demand
- According to IQVIA data, the company registered a growth of 13.2% year -on-year versus the Indian pharmaceutical market, which grew by 12.2%.
- Acute segment reported a growth of 12.3% versus the IPM, which grew by 10.1%, which is a 220 basis point outperformance.
Margins & costs
- So in terms of employee cost, yes, the growth is more than 16% in the quarter.
- But just to share the numbers, yes, there was between -- you can say, if we exclude the diligence cost and all of Occlutech, there was an EBITDA loss of around INR5 crores to INR7 crores because we are also investing into this business.
Capex & expansion
- MedTech, yes, we have completed the acquisition of Occlutech, but that was in mid of July.
- Yes, the ortho business, which we acquired, but I think small scale, at consolidated level, the impact is not that high.
Balance sheet & cash
- So I understand that had got impacted because of your receivable policies or your credit period.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.